Francis K Buadi

Francis K Buadi

UNVERIFIED PROFILE

Are you Francis K Buadi?   Register this Author

Register author
Francis K Buadi

Francis K Buadi

Publications by authors named "Francis K Buadi"

Are you Francis K Buadi?   Register this Author

100Publications

2669Reads

37Profile Views

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Biol Blood Marrow Transplant 2019 03 7;25(3):e108-e111. Epub 2018 Dec 7.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445701PMC
March 2019

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Blood 2019 02 26;133(7):652-659. Epub 2018 Dec 26.

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-825349DOI Listing
February 2019

Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia.

Neurology 2018 04;90(16):748-752

From the Department of Neurology (R.S., T.C., G.L.P.-E., E.P.F.) and Divisions of Hematology (F.K.B.), Infectious Disease (E.B.), and Hospital Internal Medicine, Department of Medicine (V.S.P.), Mayo Clinic, Rochester, MN; and College of Biological Sciences (R.S.), University of Minnesota, Minneapolis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005337DOI Listing
April 2018

Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).

Eur J Haematol 2018 Feb 16;100(2):215-217. Epub 2017 Nov 16.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12986DOI Listing
February 2018

The next generation of novel therapies for the management of relapsed multiple myeloma.

Future Oncol 2017 Jan 11;13(1):63-75. Epub 2016 Aug 11.

The Divisions of Hematology & Blood & Marrow Transplantation, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134360PMC
January 2017

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016